Does adherence to oral cancer therapy matter? Yes, says our Dr. @vanmorrismd.bsky.social.

At #AACR26, he presented strategies for improving outcomes for standard therapies and clinical trials for colorectal cancer. #EndCancer

AACR: Zedoresertib and lunresertib combination shows promising antitumor activity For patients with advanced solid tumors harboring specific genetic alterations, the first-in-class synthetic lethal combination of WEE1 inhibitor zedoresertib plus PKMYT1 inhibitor lunresertib demonst...

The results showed early clinical proof-of-concept supporting the combination of zedoresertib and lunresertib in certain advanced solid tumors with these alterations.

Read more: spr.ly/6015B6C9ac (2/2) #EndCancer

Dr. Timothy Yap giving a presentation at a podium.

"Cancers with CCNE1, FBXW7 and PPP2R1A alterations represent areas of unmet need, with no specific standard of care options," says Dr. Timothy Yap while presenting results from the Phase 1 MYTHIC trial at #AACR26. (1/2)

Congratulations to our Dr. Jim Allison on receiving this prestigious award. Learn more about the honor: bit.ly/4tUgrzb #AACR26 #EndCancer

Photo of a presentation at the AACR conference.

Congratulations to our Dr. Natalie Vokes on receiving an
@theaacr.bsky.social Trailblazer Cancer Research Grant, announced at this morning's #AACR26 opening ceremony.

This grant will support her research into CDKN2A/MTAP-deleted non-small cell lung cancer. #EndCancer

Abstracts Sunday at 2 and Monday at 2 about IBC

Excited about our @mdanderson.bsky.social Inflammatory Breast Cancer abstracts at #AACR26! Great job from our IBC lab teams! @debeblab.bsky.social

AACR: Clinical trial presentations feature advances across cancer care Researchers from The University of Texas MD Anderson Cancer Center will present initial data from five clinical trials during minisymposia at this week’s American Association for Cancer Research (AACR...

"Findings further support perioperative NIVO as an efficacious treatment option in eligible patients with resectable NSCLC and highlight potentially meaningful markers for risk stratification," she said.

Read more: bit.ly/4mNxoJl #EndCancer (2/2)

Dr. Tina Cascone delivering a presentation at a podium.

Based on the initial results from the CheckMate 77T trial,
@fda.govapproved perioperative nivolumab for the treatment of resectable non-small cell lung cancer in 2024.

At #AACR26, Dr. Tina Cascone presented additional findings derived from biomarker analyses. (1/2)

Dr. Ying Yuan develops methods and tools for data analysis. At #AACR26, he led a workshop on using Bayesian designs in early-phase clinical trials.

"The Bayesian Optimal Phase 2 design offers a highly-efficient, unified framework for futility and toxicity monitoring," he shared. #EndCancer

How natural killer cells are being engineered to target cancer #Shorts Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.

Researchers at UT MD Anderson are working to enhance natural killer cells by combining them with T cell receptor technology to improve how they recognize cancer and respond more precisely to abnormal cells.

Watch to learn more: spr.ly/63325B6ACIx

Two-time tongue cancer survivor: Why I support research at UT MD Anderson When Jessica Lutterman was told she needed a third oral surgery for a possible tongue cancer recurrence, she turned to UT MD Anderson. Find out why an immunotherapy clinical trial here inspired her to support our research

Dr. Moran Amit will present results from a clinical trial at #AACR26 that examined immunotherapy injections for patients with oral lesions.

One of the trial participants shares more on the main treatment side effect she experienced - elation: spr.ly/63324B6fCXI #OncSky #EndCancer

Top 3 UT MD Anderson abstracts at AACR 2026 Albert Koong, M.D., Ph.D., shares three abstracts that will be shared by UT MD Anderson researchers at the 2026 annual meeting of the American Association for Cancer Research. These breakthroughs in discovery science and translational research will move cancer therapies further for our patients.

From preserving quality of life for patients with oral cancer, to harnessing the power of AI for better lung cancer treatment outcomes, researchers from UT MD Anderson will be highlighting their cutting-edge work at #AACR26.

Learn more: spr.ly/6010B6fCnA @theaacr.bsky.social #OncSky #EndCancer

Cancerwise Podcast UT MD Anderson’s Cancerwise podcast features insights from our experts on cancer diagnosis and treatment, research breakthroughs, and prevention, as well as stories from survivors and caregivers who’ve faced cancer firsthand.

Cancer research is moving fast, bringing better treatments to patients sooner.

In this Cancerwise podcast episode, learn how new technologies and multimodal data are advancing precision oncology and improving cancer care.

Listen: spr.ly/63329B6fDj9

#AACR26 #EndCancer

Stage 4 kidney cancer survivor thankful he chose UT MD Anderson When Roberto Gonzalez was diagnosed with metastatic kidney cancer, he came to UT MD Anderson for treatment, which includes a combination of immunotherapy and targeted therapy. Here, he shares how a personalized treatment plan helped shrink the tumors and is allowing him more time with his family.

“I have a beautiful life,” says Roberto Gonzalez. “I don’t let the cancer diagnosis weigh on me. I know there’s a lot more for me to do in life.”

How a combination treatment at UT MD Anderson is giving him more time with his family: spr.ly/63323B6NMBh #OncSky #EndCancer

AACR: Jennifer Wargo, M.D., elected Fellow of the AACR Academy Jennifer Wargo, M.D., professor of Surgical Oncology and Genomic Medicine at The University of Texas MD Anderson Cancer Center, has been elected to the 2026 class of Fellows of the American Association for Cancer Research (AACR) Academy in recognition of her pioneering work to define interactions between the microbiome, cancer biology and treatment response.

Our Jennifer Wargo, M.D., has been elected to the 2026 @theaacr.bsky.social class of fellows in recognition of her pioneering work to define interactions between the microbiome, cancer biology and treatment response.

More about this prestigious honor: spr.ly/6012B6NHmG #AACR26 #OncSky #EndCancer

AACR: Immunotherapy pioneer James P. Allison, Ph.D., honored with Award for Lifetime Achievement in Cancer Research James P. Allison, Ph.D., Regental professor and chair of Immunology, vice president of immunobiology and founding director of the James P. Allison Institute™ at The University of Texas MD Anderson Can...

Nobel laureate James Allison, Ph.D., will be honored with the Award for Lifetime Achievement in Cancer Research at this year's @theaacr.bsky.social Annual Meeting.

More about this recognition of Dr. Allison's lifelong commitment to scientific discovery: spr.ly/6019B6230d #EndCancer

What is a menin inhibitor? What are menin inhibitors? Leukemia expert Elias Jabbour, M.D., discusses which patients make the best candidates for this novel cancer therapy, how they work and possible side effects.

Menin inhibitors are a new form of cancer treatment for certain types of leukemia.

But you may be wondering how they work and for which leukemia types? Our Dr. Elias Jabbour explains: spr.ly/63321B62yaJ #OncSky #EndCancer

Immunosuppressants: What is their role in cancer care? What are immunosuppressants? Jeremy Ramdial, M.D., explains how these drugs work, their role in stem cell transplants, and how they help manage graft vs. host disease.

Sometimes, cancer patients are given immunosuppressants as part of their treatment plan.

Our Dr. Jeremy Ramdial explains what they are, why someone may need them and how they work: spr.ly/63324B6LTa8 #OncSky #EndCancer

Okra water: Should you be drinking it? Is okra water actually good for you? Senior clinical dietician Rachel Murphy weighs in on the science behind the trend, from its alleged blood sugar and weight loss benefits to the potential risks.

Proponents of drinking okra water claim it can help with a variety of systems in your body. But do any of those claims hold up?

Clinical Dietitian Rachel Murphy shares what you should know: spr.ly/63320B6I8RG #OncSky #EndCancer

Congratulations to James P. Allison, PhD, FAACR, who has been honored with the 2026 AACR Award for Lifetime Achievement in Cancer Research. He will accept the award and deliver remarks on Sunday, April 19, at 3 p.m. PT, during #AACR26 in San Diego. Learn more: buff.ly/yBNB1qb @mdanderson.bsky.social

Researchers find new target to sensitize pancreatic tumors to immunotherapy Researchers find new target to sensitize pancreatic tumors to immunotherapy

What if there was a way to identify which patients with pancreatic cancer were more likely to benefit from immunotherapy?

A group of UT MD Anderson researchers found a biomarker that may be able to do that. Learn more: spr.ly/6012B6x8Lj #OncSky #EndCancer

Metastatic melanoma survivor trusts UT MD Anderson’s expertise and research Joe Eastin faced multiple melanoma recurrences before seeking a second opinion at UT MD Anderson. Here he shares how immunotherapy and a caring team of doctors and researchers helped him through a metastatic melanoma diagnosis.

“I think the science around advanced melanoma treatment is pretty amazing," says Joe Eastin after receiving immunotherapy for metastatic melanoma at UT MD Anderson.

Why he's excited about the future of immunotherapy research: spr.ly/63327B6aDhv #OncSky #EndCancer

Researchers identify blood-based biomarker for cancer risk in people with Lynch Syndrome Researchers identify blood-based biomarker for cancer risk in people with Lynch Syndrome

Researchers at UT MD Anderson have identified a blood-based biomarker that could help detect cancer risk earlier in people with Lynch syndrome.

Read more: spr.ly/6017B6QjF7 #OncSky #EndCancer

Blood in semen (hematospermia): Is it a sign of cancer? Blood in semen, also known as hematospermia, usually is not a sign of cancer or anything serious. But it’s also not normal. Urologic oncologist Lisly Chéry, M.D., shares when to see a doctor for blood in your semen and how it’s treated.

There are some infections or inflammatory conditions that can cause you to see blood in your semen, which can be a concerning thing to see.

But Dr. Lisly Chéry shares why it usually isn't something serious: spr.ly/63321B6tmH9 #OncSky #EndCancer

3 reasons appendix cancer is hard to diagnose  Appendix cancer is now known to be distinct from colorectal cancer. But it can still be difficult to diagnose. Why? Gastrointestinal oncologists John Paul Shen, M.D. and Beth Melmink, M.D., weigh in.

Drs. John Paul Shen and Beth Helmink recently shared why appendix cancer can be difficult to diagnose.

Read their insights here: spr.ly/63320B6UtIC #OncSky #Endcancer

Stage IV cervical cancer survivor thankful for immunotherapy clinical trial Paulette Burkhart was 70 when she was diagnosed with stage IV cervical cancer. Here she shares why she’s glad she enrolled in an immunotherapy clinical trial at UT MD Anderson and encourages others facing cancer to ask about clinical trials as well.

When Paulette Burkhart was diagnosed with advanced cervical cancer, she met with Dr. Roni Wilke, who told her about an immunotherapy clinical trial.

Two years later, the cancer has had a complete response, and Paulette is doing well: spr.ly/63324B6oFt6 #OncSky #EndCancer

Radiation therapy improves outcomes for 'supermassive' bile duct tumors A new study from researchers at The University of Texas MD Anderson Cancer Center demonstrates that a specialized high-dose type of radiation delivery may significantly improve outcomes for patients with large bile duct tumors in the liver, known as intrahepatic cholangiocarcinoma.

A new study found that a specialized high-dose type of radiation delivery may significantly improve outcomes for patients with intrahepatic cholangiocarcinoma, when given with standard-of-care chemotherapy.

Learn more: spr.ly/6019B6ovs5 #OncSky #EndCancer

Researchers from UT MD Anderson developed a first-in-class antibody that targets a protein over expressed in many cancer types, allowing for the creation of a new treatment that brings targeted radiation directly to tumor cells.

Learn more: spr.ly/6013B6o6uJ #OncSky #EndCancer

Lung cancer survivor finds care, support and connection at UT MD Anderson After Daniel West was diagnosed with lung cancer, he chose UT MD Anderson for his treatment.

“We liked that at UT MD Anderson, we were able to talk to all my doctors in the beginning," recalls Daniel West. "Lung cancer is such a serious diagnosis, so I liked that they had a plan for my treatment.”

Read his story: spr.ly/63320B6Wt4k #OncSky #EndCancer

Gleason score decoded: What it means, and how it helps guide prostate cancer treatment A Gleason score is a grading system used for prostate cancer. Pathologists derive the score after looking at prostate tissue samples under a microscope. Lisly Chéry, M.D., breaks down how Gleason scores are calculated how they’re used to guide prostate cancer treatment.

Many physicians use Gleason score and a corresponding Grade Group to grade prostate cancer and to determine the risk of spreading.

Dr. Lisly Chéry shares how your Gleason score can range from 6 to 10 and what those scores can potentially mean: spr.ly/63322B6mpVk #OncSky #EndCancer